ADC · HER2+ 유방암

58개 · ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved58 programs
ADCStandard DatabasestaleGileadPhase 2

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, Sacituzumab Govitecan / Trastuzumab Deruxtecan)

Triple Negative Breast Neoplasms; Neoplasm Metastasis · Triple Negative Breast Neoplasms

#TripleNegativeBreastNeoplasms#ADC#Phase2#antibody-drug-conjugate#NeoplasmMetastasis+1
Trials 24Status Recruiting
ADCStandard DatabasestaleByondis B.V.Phase 3

trastuzumab (Herceptin, vic-, (vic-)trastuzumab duocarmazine)

Metastatic Breast Cancer · Metastatic Breast Cancer

#MetastaticBreastCancer#ADC#Phase3#antibody-drug-conjugate#Byondis
Trials 23Status Active
ADCStandard DatabasestaleRochePhase 2

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, HER2,trastuzumab deruxtecan± pertuzumab)

Salivary Gland Carcinoma; Precision Therapy · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#SalivaryGlandCarcinoma+2
Trials 23Status Recruiting
ADCLimited DatastaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin Tislelizumab)

Her2 Overexpressing High-Risk Non-Muscle Invasive Bladder Urothelial Carcinoma · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#Her2OverexpressingHigh-RiskNon-M+1
Trials 17Status Active
ADCLimited DatastaleRemeGenApproved

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin combined with Tislelizumab)

Breast Cancer; Neoadjuvant Therapy · Breast Cancer

#BreastCancer#ADC#Approved#antibody-drug-conjugate#NeoadjuvantTherapy+1
Trials 17Status Active
ADCStandard DatabasestaleDaiichi SankyoPhase 3

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, T-Dxd + Pertuzumab)

HER2 + Breast Cancer · HER2

#HER2#ADC#Phase3#antibody-drug-conjugate#HER2+BreastCancer+1
Trials 17Status Recruiting
ADCStandard DatabasestaleAstraZenecaPhase 2

durvalumab (Imfinzi, Datopotamab deruxtecan + Durvalumab)

Breast Neoplasms; Breast Cancer · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#BreastNeoplasms+2
Trials 11Status Recruiting
ADCStandard DatabasestaleMerck Sharp & Dohme LLCPhase 2

Zilovertamab vedotin (Zilovertamab vedotin)

Lymphoma, Large B-Cell, Diffuse · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#Lymphoma+3
Trials 10Status Active
ADCStandard DatabasestaleQuantumLeap Healthcare Collabor…Phase 2

[vic-]trastuzumab duocarmazine (SYD985, SYD985 ([vic-]trastuzumab duocarmazine))

Breast Neoplasms; Breast Cancer · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#BreastNeoplasms+2
Trials 7Status Recruiting
ADCLimited DatastaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin Plus Cadonilimab)

Bile Duct Adenocarcinoma Non-Resectable; HER2 Gene Mutation · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#BileDuctAdenocarcinomaNon-Resect+2
Trials 6Status Active
ADCStandard DatabasestaleRochePhase 2

trastuzumab (Herceptin, Trastuzumab emtansine [Kadcyla])

Metastatic Breast Cancer · Metastatic Breast Cancer

#MetastaticBreastCancer#ADC#Phase2#antibody-drug-conjugate#Roche
Trials 5Status Active
ADCStandard DatabasestaleSeagen Inc.Phase 2

ladiratuzumab vedotin (ladiratuzumab vedotin)

Small Cell Lung Cancer; Non-small Cell Lung Cancer, Squamous · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#SmallCellLungCancer+3
Trials 5Status Active
ADCLimited DatastaleRochePhase 2

trastuzumab (Herceptin, Patritumab and Trastuzumab)

Breast Neoplasms; Breast Cancer · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#BreastNeoplasms+2
Trials 4Status Recruiting
ADCLimited DatastaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin+Anlotinib)

Breast Cancer · Breast Cancer

#BreastCancer#ADC#Phase2#antibody-drug-conjugate#RemeGen
Trials 3Status Active
ADCLimited DatastaleRochePhase 1

trastuzumab (Herceptin, trastuzumab-MCC-DM1)

Metastatic Breast Cancer · MET

#MET#ADC#Phase1#antibody-drug-conjugate#MetastaticBreastCancer+1
Trials 3Status Active
ADCStandard DatabasestaleMacroGenicsPhase 2

vobramitamab duocarmazine (vobramitamab duocarmazine)

Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Cancer · Advanced Solid Tumor

#AdvancedSolidTumor#ADC#Phase2#antibody-drug-conjugate#SquamousCellCarcinomaofHeadandNe+2
Trials 3Status Discontinued
ADCLimited DatastaleThe First Affiliated Hospital w…Preclinical

Disitamb Vedotin (Disitamb Vedotin)

Breast Cancer · Breast Cancer

#BreastCancer#ADC#Preclinical#antibody-drug-conjugate#The
Trials 2Status Active
ADCLimited DatastaleJiangsu HengruiPhase 2

A2: SHR-A1811 with Camrelizumab with famitinib (A2: SHR-A1811 with Camrelizumab with famitinib)

Triple-negative Breast Cancer · Triple-negative Breast Cancer

#Triple-negativeBreastCancer#ADC#Phase2#antibody-drug-conjugate#Jiangsu
Trials 1Status Recruiting
ADCLimited DatastaleFudan UniversityPhase 2

B2: TROP2 ADC with Camrelizumab (B2: TROP2 ADC with Camrelizumab)

Triple-negative Breast Cancer · TROP2

#TROP2#ADC#Phase2#antibody-drug-conjugate#Triple-negativeBreastCancer+1
Trials 1Status Recruiting
ADCLimited DatastaleRemeGenApproved

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin Combined With Fruquintinib)

HER2; Colorectal Cancer · HER2

#HER2#ADC#Approved#antibody-drug-conjugate#ColorectalCancer+1
Trials 1Status Active

2 / 3 pages

← PreviousNext →